WAVE Life Sciences (WVE) Competitors

WAVE Life Sciences logo
$2.86 +0.02 (+0.53%)
As of 09:52 AM Eastern
This is a fair market value price provided by Massive. Learn more.

WVE vs. BEAM, NAMS, CLDX, PVLA, and LKFT

Should you buy WAVE Life Sciences stock or one of its competitors? WAVE Life Sciences's main competitors and comparable companies include Beam Therapeutics (BEAM), NewAmsterdam Pharma (NAMS), Celldex Therapeutics (CLDX), Palvella Therapeutics (PVLA), and Lakefront Biotherapeutics American Depositary Shares (LKFT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does WAVE Life Sciences compare to Beam Therapeutics?

Beam Therapeutics (NASDAQ:BEAM) and WAVE Life Sciences (NASDAQ:WVE) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, media sentiment, dividends, earnings, valuation and risk.

Beam Therapeutics has higher revenue and earnings than WAVE Life Sciences. Beam Therapeutics is trading at a lower price-to-earnings ratio than WAVE Life Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Beam Therapeutics$139.74M15.29-$79.99M-$1.04N/A
WAVE Life Sciences$42.73M13.11-$204.38M-$1.07N/A

Beam Therapeutics has a beta of 2.23, meaning that its stock price is 123% more volatile than the broader market. Comparatively, WAVE Life Sciences has a beta of -1.4, meaning that its stock price is 240% less volatile than the broader market.

99.7% of Beam Therapeutics shares are owned by institutional investors. Comparatively, 89.7% of WAVE Life Sciences shares are owned by institutional investors. 3.8% of Beam Therapeutics shares are owned by company insiders. Comparatively, 24.3% of WAVE Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Beam Therapeutics has a net margin of -73.04% compared to WAVE Life Sciences' net margin of -296.86%. Beam Therapeutics' return on equity of -32.76% beat WAVE Life Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Beam Therapeutics-73.04% -32.76% -25.80%
WAVE Life Sciences -296.86%-44.66%-36.80%

Beam Therapeutics currently has a consensus price target of $47.64, indicating a potential upside of 130.68%. WAVE Life Sciences has a consensus price target of $20.44, indicating a potential upside of 619.87%. Given WAVE Life Sciences' stronger consensus rating and higher probable upside, analysts clearly believe WAVE Life Sciences is more favorable than Beam Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Beam Therapeutics
1 Sell rating(s)
2 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
2.75
WAVE Life Sciences
1 Sell rating(s)
2 Hold rating(s)
15 Buy rating(s)
2 Strong Buy rating(s)
2.90

In the previous week, WAVE Life Sciences had 1 more articles in the media than Beam Therapeutics. MarketBeat recorded 8 mentions for WAVE Life Sciences and 7 mentions for Beam Therapeutics. Beam Therapeutics' average media sentiment score of 0.73 beat WAVE Life Sciences' score of -0.23 indicating that Beam Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Beam Therapeutics
1 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
WAVE Life Sciences
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
4 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Beam Therapeutics beats WAVE Life Sciences on 10 of the 16 factors compared between the two stocks.

How does WAVE Life Sciences compare to NewAmsterdam Pharma?

WAVE Life Sciences (NASDAQ:WVE) and NewAmsterdam Pharma (NASDAQ:NAMS) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, earnings, valuation, profitability, dividends, institutional ownership, analyst recommendations and media sentiment.

NewAmsterdam Pharma has lower revenue, but higher earnings than WAVE Life Sciences. NewAmsterdam Pharma is trading at a lower price-to-earnings ratio than WAVE Life Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
WAVE Life Sciences$42.73M13.11-$204.38M-$1.07N/A
NewAmsterdam Pharma$22.50M103.35-$203.82M-$1.69N/A

WAVE Life Sciences has a net margin of -296.86% compared to NewAmsterdam Pharma's net margin of -789.95%. NewAmsterdam Pharma's return on equity of -31.39% beat WAVE Life Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
WAVE Life Sciences-296.86% -44.66% -36.80%
NewAmsterdam Pharma -789.95%-31.39%-28.32%

89.7% of WAVE Life Sciences shares are owned by institutional investors. Comparatively, 89.9% of NewAmsterdam Pharma shares are owned by institutional investors. 24.3% of WAVE Life Sciences shares are owned by company insiders. Comparatively, 12.7% of NewAmsterdam Pharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, WAVE Life Sciences and WAVE Life Sciences both had 8 articles in the media. NewAmsterdam Pharma's average media sentiment score of 0.32 beat WAVE Life Sciences' score of -0.23 indicating that NewAmsterdam Pharma is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
WAVE Life Sciences
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
4 Negative mention(s)
0 Very Negative mention(s)
Neutral
NewAmsterdam Pharma
2 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

WAVE Life Sciences presently has a consensus target price of $20.44, suggesting a potential upside of 619.87%. NewAmsterdam Pharma has a consensus target price of $49.82, suggesting a potential upside of 156.93%. Given WAVE Life Sciences' stronger consensus rating and higher probable upside, equities research analysts plainly believe WAVE Life Sciences is more favorable than NewAmsterdam Pharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
WAVE Life Sciences
1 Sell rating(s)
2 Hold rating(s)
15 Buy rating(s)
2 Strong Buy rating(s)
2.90
NewAmsterdam Pharma
1 Sell rating(s)
1 Hold rating(s)
9 Buy rating(s)
1 Strong Buy rating(s)
2.83

WAVE Life Sciences has a beta of -1.4, suggesting that its stock price is 240% less volatile than the broader market. Comparatively, NewAmsterdam Pharma has a beta of 0.15, suggesting that its stock price is 85% less volatile than the broader market.

Summary

WAVE Life Sciences beats NewAmsterdam Pharma on 9 of the 16 factors compared between the two stocks.

How does WAVE Life Sciences compare to Celldex Therapeutics?

Celldex Therapeutics (NASDAQ:CLDX) and WAVE Life Sciences (NASDAQ:WVE) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, earnings, valuation, media sentiment, profitability and analyst recommendations.

Celldex Therapeutics presently has a consensus price target of $64.08, suggesting a potential upside of 128.54%. WAVE Life Sciences has a consensus price target of $20.44, suggesting a potential upside of 619.87%. Given WAVE Life Sciences' stronger consensus rating and higher possible upside, analysts plainly believe WAVE Life Sciences is more favorable than Celldex Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Celldex Therapeutics
1 Sell rating(s)
1 Hold rating(s)
11 Buy rating(s)
0 Strong Buy rating(s)
2.77
WAVE Life Sciences
1 Sell rating(s)
2 Hold rating(s)
15 Buy rating(s)
2 Strong Buy rating(s)
2.90

WAVE Life Sciences has higher revenue and earnings than Celldex Therapeutics. Celldex Therapeutics is trading at a lower price-to-earnings ratio than WAVE Life Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Celldex Therapeutics$1.54M1,430.40-$258.76M-$4.30N/A
WAVE Life Sciences$42.73M13.11-$204.38M-$1.07N/A

Celldex Therapeutics has a net margin of 0.00% compared to WAVE Life Sciences' net margin of -296.86%. WAVE Life Sciences' return on equity of -44.66% beat Celldex Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Celldex TherapeuticsN/A -52.66% -47.58%
WAVE Life Sciences -296.86%-44.66%-36.80%

Celldex Therapeutics has a beta of 1.04, suggesting that its stock price is 4% more volatile than the broader market. Comparatively, WAVE Life Sciences has a beta of -1.4, suggesting that its stock price is 240% less volatile than the broader market.

89.7% of WAVE Life Sciences shares are held by institutional investors. 5.2% of Celldex Therapeutics shares are held by company insiders. Comparatively, 24.3% of WAVE Life Sciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, WAVE Life Sciences had 7 more articles in the media than Celldex Therapeutics. MarketBeat recorded 8 mentions for WAVE Life Sciences and 1 mentions for Celldex Therapeutics. Celldex Therapeutics' average media sentiment score of 0.93 beat WAVE Life Sciences' score of -0.23 indicating that Celldex Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Celldex Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
WAVE Life Sciences
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
4 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

WAVE Life Sciences beats Celldex Therapeutics on 12 of the 16 factors compared between the two stocks.

How does WAVE Life Sciences compare to Palvella Therapeutics?

WAVE Life Sciences (NASDAQ:WVE) and Palvella Therapeutics (NASDAQ:PVLA) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, profitability, media sentiment, valuation, institutional ownership, analyst recommendations, risk and dividends.

WAVE Life Sciences currently has a consensus price target of $20.44, suggesting a potential upside of 619.87%. Palvella Therapeutics has a consensus price target of $214.86, suggesting a potential upside of 48.84%. Given WAVE Life Sciences' higher possible upside, research analysts clearly believe WAVE Life Sciences is more favorable than Palvella Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
WAVE Life Sciences
1 Sell rating(s)
2 Hold rating(s)
15 Buy rating(s)
2 Strong Buy rating(s)
2.90
Palvella Therapeutics
1 Sell rating(s)
0 Hold rating(s)
13 Buy rating(s)
2 Strong Buy rating(s)
3.00

Palvella Therapeutics has higher revenue and earnings than WAVE Life Sciences. Palvella Therapeutics is trading at a lower price-to-earnings ratio than WAVE Life Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
WAVE Life Sciences$42.73M13.11-$204.38M-$1.07N/A
Palvella Therapeutics$42.81M49.30-$41.72M-$5.50N/A

Palvella Therapeutics has a net margin of 0.00% compared to WAVE Life Sciences' net margin of -296.86%. Palvella Therapeutics' return on equity of -44.44% beat WAVE Life Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
WAVE Life Sciences-296.86% -44.66% -36.80%
Palvella Therapeutics N/A -44.44%-36.75%

WAVE Life Sciences has a beta of -1.4, suggesting that its stock price is 240% less volatile than the broader market. Comparatively, Palvella Therapeutics has a beta of -0.21, suggesting that its stock price is 121% less volatile than the broader market.

89.7% of WAVE Life Sciences shares are owned by institutional investors. Comparatively, 40.1% of Palvella Therapeutics shares are owned by institutional investors. 24.3% of WAVE Life Sciences shares are owned by company insiders. Comparatively, 17.2% of Palvella Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Palvella Therapeutics had 1 more articles in the media than WAVE Life Sciences. MarketBeat recorded 9 mentions for Palvella Therapeutics and 8 mentions for WAVE Life Sciences. Palvella Therapeutics' average media sentiment score of 0.99 beat WAVE Life Sciences' score of -0.23 indicating that Palvella Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
WAVE Life Sciences
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
4 Negative mention(s)
0 Very Negative mention(s)
Neutral
Palvella Therapeutics
4 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Palvella Therapeutics beats WAVE Life Sciences on 10 of the 15 factors compared between the two stocks.

How does WAVE Life Sciences compare to Lakefront Biotherapeutics American Depositary Shares?

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) and WAVE Life Sciences (NASDAQ:WVE) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, valuation, media sentiment, dividends, analyst recommendations, institutional ownership and profitability.

32.5% of Lakefront Biotherapeutics American Depositary Shares shares are held by institutional investors. Comparatively, 89.7% of WAVE Life Sciences shares are held by institutional investors. 2.9% of Lakefront Biotherapeutics American Depositary Shares shares are held by company insiders. Comparatively, 24.3% of WAVE Life Sciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Lakefront Biotherapeutics American Depositary Shares has higher revenue and earnings than WAVE Life Sciences. Lakefront Biotherapeutics American Depositary Shares is trading at a lower price-to-earnings ratio than WAVE Life Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lakefront Biotherapeutics American Depositary Shares$1.26B1.80$363.05M-$1.41N/A
WAVE Life Sciences$42.73M13.11-$204.38M-$1.07N/A

Lakefront Biotherapeutics American Depositary Shares currently has a consensus target price of $36.00, suggesting a potential upside of 4.68%. WAVE Life Sciences has a consensus target price of $20.44, suggesting a potential upside of 619.87%. Given WAVE Life Sciences' stronger consensus rating and higher possible upside, analysts plainly believe WAVE Life Sciences is more favorable than Lakefront Biotherapeutics American Depositary Shares.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Lakefront Biotherapeutics American Depositary Shares
0 Sell rating(s)
5 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
2.50
WAVE Life Sciences
1 Sell rating(s)
2 Hold rating(s)
15 Buy rating(s)
2 Strong Buy rating(s)
2.90

Lakefront Biotherapeutics American Depositary Shares has a net margin of 0.00% compared to WAVE Life Sciences' net margin of -296.86%. Lakefront Biotherapeutics American Depositary Shares' return on equity of 0.00% beat WAVE Life Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Lakefront Biotherapeutics American Depositary SharesN/A N/A N/A
WAVE Life Sciences -296.86%-44.66%-36.80%

In the previous week, Lakefront Biotherapeutics American Depositary Shares had 10 more articles in the media than WAVE Life Sciences. MarketBeat recorded 18 mentions for Lakefront Biotherapeutics American Depositary Shares and 8 mentions for WAVE Life Sciences. Lakefront Biotherapeutics American Depositary Shares' average media sentiment score of 0.92 beat WAVE Life Sciences' score of -0.23 indicating that Lakefront Biotherapeutics American Depositary Shares is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Lakefront Biotherapeutics American Depositary Shares
7 Very Positive mention(s)
3 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
WAVE Life Sciences
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
4 Negative mention(s)
0 Very Negative mention(s)
Neutral

Lakefront Biotherapeutics American Depositary Shares has a beta of 0.22, indicating that its stock price is 78% less volatile than the broader market. Comparatively, WAVE Life Sciences has a beta of -1.4, indicating that its stock price is 240% less volatile than the broader market.

Summary

WAVE Life Sciences beats Lakefront Biotherapeutics American Depositary Shares on 9 of the 17 factors compared between the two stocks.

Get WAVE Life Sciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for WVE and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding WVE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

WVE vs. The Competition

MetricWAVE Life SciencesBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$565.06M$4.06B$7.83B$11.74B
Dividend YieldN/A3.63%2.47%4.47%
P/E Ratio-2.6826.7033.9728.44
Price / Sales13.1815.788.495.70
Price / CashN/A22.9521.0121.90
Price / Book1.404.184.453.72
Net Income-$204.38M-$24.15M$3.52B$393.10M
7 Day Performance-16.52%-7.79%-5.94%-5.77%
1 Month Performance-8.79%-5.95%-4.58%-7.14%
1 Year Performance-59.85%-8.08%-1.95%-7.47%

WAVE Life Sciences Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
WVE
WAVE Life Sciences
2.6373 of 5 stars
$2.86
+0.5%
$20.44
+616.1%
-60.3%$565.06M$42.73MN/A317
BEAM
Beam Therapeutics
2.6814 of 5 stars
$22.86
-4.9%
$47.64
+108.3%
-6.2%$2.49B$139.74MN/A540
NAMS
NewAmsterdam Pharma
3.3709 of 5 stars
$20.14
+0.9%
$49.82
+147.4%
-49.7%$2.40B$22.50MN/A100
CLDX
Celldex Therapeutics
1.8936 of 5 stars
$28.83
+1.1%
$64.08
+122.3%
+7.8%$2.24B$1.54MN/A198
PVLA
Palvella Therapeutics
2.6123 of 5 stars
$152.48
-0.5%
$213.85
+40.2%
+76.8%$2.24B$42.81MN/A29

Related Companies and Tools


This page (NASDAQ:WVE) was last updated on 11/18/2026 by MarketBeat.com Staff.
From Our Partners